Novartis
Top Ten most popular articles on Pharmafile.com this week
January 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten
It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …
Novartis enters biosimilar agreement with Biocon
January 19, 2018Medical Communications, Sales and Marketing Biocon, Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical
Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and …
Novartis’ CAR T therapy Kymriah scores accelerated approval in both Europe and US
January 17, 2018Research and Development, Sales and Marketing CAR T, CAR-T, EMA, Europe, FDA, Kymriah, Novartis, US, pharma
Following up last year’s ground-breaking news that CAR T therapy Kymriah had become the first such treatment to be approved …
Novartis debuts new data showing Cosentyx’s superiority over Janssen’s Stelara in psoriasis
January 16, 2018Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma
Novartis has lifted the curtain on new data comparing the efficacy of Cosentyx (secukinumab) to Janssen’s Stelara (ustekinumab) in achieving …
Novartis prises Pfizer’s Oncology Head away
January 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Pfizer, biotech, drugs, pharma, pharmaceutical
Novartis has been looking to find someone to fill the shoes of Bruno Strigini since it was revealed that he …
Novartis’ Kisqali gains breakthrough status in premenopausal breast cancer
January 3, 2018Research and Development, Sales and Marketing Kisqali, Novartis, biotech, drugs, pharma, pharmaceutical
Novartis has received a major boost in its efforts to broaden use of its CDK4/6 inhibitor, by receiving a breakthrough …
Novartis hit by court loss, could spur numerous cases across industry
December 22, 2017Medical Communications, Sales and Marketing Novartis, biotech, drugs, pharma, pharmaceutical
In a landmark ruling, a Californian court has found that a brand name manufacturer of a drug could be held …
NICE recommends Novartis’ Extavia for MS, but knocks back a raft of other beta interferons
December 20, 2017Research and Development, Sales and Marketing Extavia, MS, NICE, Novartis, beta interferon, multiple sclerosis
NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia (interferon beta 1b) for the treatment of …
Novartis snaps up Priority Review Voucher for $130m
December 18, 2017Manufacturing and Production, Sales and Marketing Novartis, Ultragenyx, biotech, drugs, pharma, pharmaceutical
Novartis has got its wallet out to pick up a Priority Review Voucher (PRV) from Ultragenyx, forking out $130 million …
New PARP inhibitor hits UK market, offering distinct advantage
December 18, 2017Sales and Marketing AstraZeneca, Novartis, Tesaro, Zejula, biotech, drugs, lynparza, pharma, pharmaceutical
Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP …
Novartis’ President of Oncology announces retirement
December 15, 2017Medical Communications Bruno Strigini, Novartis, pharma
Novartis has announced that the President of its oncology business, Bruno Strigini, is to retire next year, citing personal reasons …
Novartis, Abbott targeted by Indian watchdog over allegations of price collusion
December 14, 2017Sales and Marketing Abbott, Emcure Pharma, Galdus, Novartis, USV, diabetes, pharma, vildagliptin
Novartis, Abbott, Emcure Pharma and USV have become the targets of an investigation by the Competition Commission of India (CCI) …
Novartis Kisqali improves PFS in younger women
December 7, 2017Research and Development Kisqali, Novartis, biotech, drugs, pharma, pharmaceutical
A Phase 3 trial looking at the use of Kisqali (ribociclib) to treat premenopausal or perimenopausal women with hormone-receptor positive, …
Two big pharma companies accused of false marketing
December 6, 2017Research and Development, Sales and Marketing GSK, Novartis, biotech, drugs, pharma, pharmaceutical
Novartis and GSK have been taken to court by the Australian Competition and Consumer Commission (ACCC) over allegations of falsely …
Novartis nets first acute myeloid leukaemia approval in Canada, but NICE says no
December 6, 2017Research and Development, Sales and Marketing Canada, NICE, Novartis, Rydapt, UK, acute myeloid leukaemia, leukaemia, pharma
Novartis is celebrating the news that its drug Rydapt (midostaurin) has been awarded marketing approval in Canada for the treatment …
Latest content
FibroFind appoints Lee Borthwick as CEO
